{"transactions":[{"id":4615575,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-11T11:30:03.000Z","date":"2026-09-10","kind":"purchase","planned":false,"acquired":true,"shares":79800,"price":4.25,"value":339150.0,"ownership":{"direct":true},"balance_after":1000000,"source":{"system":"sec-edgar","filing":"0001213900-26-098970","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390026098970/ownership.xml","form_type":"4"}},{"id":4615574,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-11T11:30:03.000Z","date":"2026-09-09","kind":"purchase","planned":false,"acquired":true,"shares":120200,"price":4.2,"value":504840.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $4.16 to $4.20 per share, inclusive."}],"balance_after":920200,"source":{"system":"sec-edgar","filing":"0001213900-26-098970","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390026098970/ownership.xml","form_type":"4"}},{"id":4615577,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-11T11:30:02.000Z","date":"2026-09-10","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":4.1,"value":410000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchase prices range from $4.03 to $4.11 per share, inclusive"}],"balance_after":1500000,"source":{"system":"sec-edgar","filing":"0001213900-26-098969","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1565832/000121390026098969/ownership.xml","form_type":"4"}},{"id":4615576,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-11T11:30:02.000Z","date":"2026-09-09","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":4.18,"value":418000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $4.15 to $4.22 per share, inclusive."}],"balance_after":1400000,"source":{"system":"sec-edgar","filing":"0001213900-26-098969","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1565832/000121390026098969/ownership.xml","form_type":"4"}},{"id":967123,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Appreciation Rights","published_at":"2025-12-16T14:30:49.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":1198000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026."}],"balance_after":1198000,"derivative":{"exercise_price":4.06,"exercise_date":"2026-03-12","expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":1198000},"source":{"system":"sec-edgar","filing":"0001213900-25-121974","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025121974/ownership.xml","form_type":"4"}},{"id":967122,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T14:30:49.000Z","date":"2025-12-15","kind":"purchase","planned":false,"acquired":true,"shares":27500,"price":4.12,"value":113300.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $4.10 to $4.12 per share, inclusive."}],"balance_after":1300000,"source":{"system":"sec-edgar","filing":"0001213900-25-121974","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025121974/ownership.xml","form_type":"4"}},{"id":967121,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71409,"kind":"person","name":"Ence Chuck","position":1,"cik":"0001697779","reported_name":"Ence Chuck","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CA and CO"}}],"security":"Stock Appreciation Rights","published_at":"2025-12-16T14:30:04.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":828000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026."}],"balance_after":828000,"derivative":{"exercise_price":4.06,"exercise_date":"2026-03-12","expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":828000},"source":{"system":"sec-edgar","filing":"0001213900-25-121972","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025121972/ownership.xml","form_type":"4"}},{"id":967120,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71408,"kind":"person","name":"Fedeli Fabiana","position":1,"cik":"0001961902","reported_name":"Fedeli Fabiana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Appreciation Rights","published_at":"2025-12-16T14:29:40.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":164000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026."}],"balance_after":164000,"derivative":{"exercise_price":4.06,"exercise_date":"2026-03-12","expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":164000},"source":{"system":"sec-edgar","filing":"0001213900-25-121971","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025121971/ownership.xml","form_type":"4"}},{"id":967119,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71407,"kind":"person","name":"GLASSPOOL JOHN","position":1,"cik":"0001644079","reported_name":"GLASSPOOL JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Appreciation Rights","published_at":"2025-12-16T14:29:12.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":164000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026."}],"balance_after":164000,"derivative":{"exercise_price":4.06,"exercise_date":"2026-03-12","expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":164000},"source":{"system":"sec-edgar","filing":"0001213900-25-121969","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025121969/ownership.xml","form_type":"4"}},{"id":968042,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":26788,"kind":"person","name":"CASAMENTO CHARLES J","position":1,"cik":"0001117167","reported_name":"CASAMENTO CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Appreciation Rights","published_at":"2025-12-16T14:28:38.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":164000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026."}],"balance_after":164000,"derivative":{"exercise_price":4.06,"exercise_date":"2026-03-12","expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":164000},"source":{"system":"sec-edgar","filing":"0001213900-25-121967","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117167/000121390025121967/ownership.xml","form_type":"4"}},{"id":967575,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Appreciation Rights","published_at":"2025-12-16T09:30:24.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":828000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026."}],"balance_after":828000,"derivative":{"exercise_price":4.06,"exercise_date":"2026-03-12","expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":828000},"source":{"system":"sec-edgar","filing":"0001213900-25-121973","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390025121973/ownership.xml","form_type":"4"}},{"id":967574,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-16T09:30:24.000Z","date":"2025-12-15","kind":"purchase","planned":false,"acquired":true,"shares":11665,"price":4.12,"value":48059.8,"ownership":{"direct":true},"balance_after":800000,"source":{"system":"sec-edgar","filing":"0001213900-25-121973","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390025121973/ownership.xml","form_type":"4"}},{"id":967573,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71428,"kind":"person","name":"Kelly Paul Edward","position":1,"cik":"0001658544","reported_name":"Kelly Paul Edward","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Appreciation Rights","published_at":"2025-12-16T09:28:48.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":828000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026."}],"balance_after":828000,"derivative":{"exercise_price":4.06,"exercise_date":"2026-03-12","expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":828000},"source":{"system":"sec-edgar","filing":"0001213900-25-121968","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658544/000121390025121968/ownership.xml","form_type":"4"}},{"id":1005608,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71409,"kind":"person","name":"Ence Chuck","position":1,"cik":"0001697779","reported_name":"Ence Chuck","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CAO and COO"}}],"security":"Common Stock","published_at":"2025-11-06T12:30:05.000Z","date":"2025-11-05","kind":"purchase","planned":false,"acquired":true,"shares":136000,"price":2.2,"value":299200.0,"ownership":{"direct":true},"balance_after":403931,"source":{"system":"sec-edgar","filing":"0001213900-25-106838","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025106838/ownership.xml","form_type":"4"}},{"id":1005606,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-06T12:30:04.000Z","date":"2025-11-05","kind":"purchase","planned":false,"acquired":true,"shares":272500,"price":2.2,"value":599500.0,"ownership":{"direct":true},"balance_after":1272500,"source":{"system":"sec-edgar","filing":"0001213900-25-106837","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025106837/ownership.xml","form_type":"4"}},{"id":1005798,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-06T07:30:07.000Z","date":"2025-11-05","kind":"purchase","planned":false,"acquired":true,"shares":500000,"price":2.2,"value":1100000.0,"ownership":{"direct":true},"balance_after":788335,"source":{"system":"sec-edgar","filing":"0001213900-25-106836","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390025106836/ownership.xml","form_type":"4"}},{"id":1005794,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71428,"kind":"person","name":"Kelly Paul Edward","position":1,"cik":"0001658544","reported_name":"Kelly Paul Edward","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-11-06T07:30:02.000Z","date":"2025-11-05","kind":"purchase","planned":false,"acquired":true,"shares":90000,"price":2.2,"value":198000.0,"ownership":{"direct":true},"balance_after":502295,"source":{"system":"sec-edgar","filing":"0001213900-25-106835","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658544/000121390025106835/ownership.xml","form_type":"4"}},{"id":1053449,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-08-28T20:56:35.000Z","date":"2025-08-28","kind":"purchase","planned":false,"acquired":true,"shares":55976,"price":0.74,"value":41422.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Purchase prices range from $0.68 to $0.79 per share, inclusive."}],"balance_after":1000000,"source":{"system":"sec-edgar","filing":"0001213900-25-081837","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025081837/ownership.xml","form_type":"4"}},{"id":1053448,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-08-28T20:56:35.000Z","date":"2025-08-27","kind":"purchase","planned":false,"acquired":true,"shares":129455,"price":0.67,"value":86734.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchase prices range from $0.65 to $0.69 per share, inclusive."}],"balance_after":944024,"source":{"system":"sec-edgar","filing":"0001213900-25-081837","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025081837/ownership.xml","form_type":"4"}},{"id":1053447,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-08-28T20:56:35.000Z","date":"2025-08-26","kind":"purchase","planned":false,"acquired":true,"shares":80545,"price":0.62,"value":49937.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $0.61 to $0.65 per share, inclusive."}],"balance_after":814569,"source":{"system":"sec-edgar","filing":"0001213900-25-081837","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025081837/ownership.xml","form_type":"4"}},{"id":1098994,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71409,"kind":"person","name":"Ence Chuck","position":1,"cik":"0001697779","reported_name":"Ence Chuck","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CA and CO"}}],"security":"Stock Option (right to buy)","published_at":"2025-06-30T23:29:16.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 16 equal quarterly installments commencing on September 26, 2025."}],"balance_after":400000,"derivative":{"exercise_price":0.67,"exercise_date":"2025-09-26","expiration_date":"2035-06-26","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001213900-25-059870","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025059870/ownership.xml","form_type":"4"}},{"id":1098993,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-06-30T23:28:46.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 16 equal quarterly installments commencing on September 26, 2025."}],"balance_after":800000,"derivative":{"exercise_price":0.67,"exercise_date":"2025-09-26","expiration_date":"2035-06-26","underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0001213900-25-059868","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025059868/ownership.xml","form_type":"4"}},{"id":1099535,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":26788,"kind":"person","name":"CASAMENTO CHARLES J","position":1,"cik":"0001117167","reported_name":"CASAMENTO CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-30T23:28:32.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 16 equal quarterly installments commencing on September 26, 2025."}],"balance_after":100000,"derivative":{"exercise_price":0.67,"exercise_date":"2025-09-26","expiration_date":"2035-06-26","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-25-059867","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117167/000121390025059867/ownership.xml","form_type":"4"}},{"id":1098992,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71407,"kind":"person","name":"GLASSPOOL JOHN","position":1,"cik":"0001644079","reported_name":"GLASSPOOL JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-30T23:28:18.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 16 equal quarterly installments commencing on September 26, 2025."}],"balance_after":100000,"derivative":{"exercise_price":0.67,"exercise_date":"2025-09-26","expiration_date":"2035-06-26","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-25-059866","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025059866/ownership.xml","form_type":"4"}},{"id":1098991,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71408,"kind":"person","name":"Fedeli Fabiana","position":1,"cik":"0001961902","reported_name":"Fedeli Fabiana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-30T23:28:03.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 16 equal quarterly installments commencing on September 26, 2025."}],"balance_after":100000,"derivative":{"exercise_price":0.67,"exercise_date":"2025-09-26","expiration_date":"2035-06-26","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-25-059865","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025059865/ownership.xml","form_type":"4"}},{"id":1099248,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-06-30T19:29:01.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 16 equal quarterly installments commencing on September 26, 2025."}],"balance_after":600000,"derivative":{"exercise_price":0.67,"exercise_date":"2025-09-26","expiration_date":"2035-06-26","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001213900-25-059869","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390025059869/ownership.xml","form_type":"4"}},{"id":1099247,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71428,"kind":"person","name":"Kelly Paul Edward","position":1,"cik":"0001658544","reported_name":"Kelly Paul Edward","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-06-30T19:27:46.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 16 equal quarterly installments commencing on September 26, 2025."}],"balance_after":400000,"derivative":{"exercise_price":0.67,"exercise_date":"2025-09-26","expiration_date":"2035-06-26","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001213900-25-059864","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658544/000121390025059864/ownership.xml","form_type":"4"}},{"id":1140066,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71409,"kind":"person","name":"Ence Chuck","position":1,"cik":"0001697779","reported_name":"Ence Chuck","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CA and CO"}}],"security":"Common Stock","published_at":"2025-05-20T22:02:33.000Z","date":"2025-05-16","kind":"purchase","planned":false,"acquired":true,"shares":228961,"price":0.4513,"value":103330.0993,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $0.401 to $0.4892 per share, inclusive."}],"balance_after":267931,"source":{"system":"sec-edgar","filing":"0001213900-25-046086","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025046086/ownership.xml","form_type":"4"}},{"id":1140065,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-05-20T22:01:43.000Z","date":"2025-05-20","kind":"purchase","planned":false,"acquired":true,"shares":147686,"price":0.5569,"value":82246.3334,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Purchase prices range from $0.53 to $0.59 per share, inclusive."}],"balance_after":734024,"source":{"system":"sec-edgar","filing":"0001213900-25-046085","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025046085/ownership.xml","form_type":"4"}},{"id":1140064,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-05-20T22:01:43.000Z","date":"2025-05-19","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":0.4998,"value":14994.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchase prices range from $0.4998 to $0.50 per share, inclusive."}],"balance_after":586338,"source":{"system":"sec-edgar","filing":"0001213900-25-046085","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025046085/ownership.xml","form_type":"4"}},{"id":1140063,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-05-20T22:01:43.000Z","date":"2025-05-16","kind":"purchase","planned":false,"acquired":true,"shares":172314,"price":0.4496,"value":77472.3744,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $0.4485 to $0.4564 per share, inclusive."}],"balance_after":556338,"source":{"system":"sec-edgar","filing":"0001213900-25-046085","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025046085/ownership.xml","form_type":"4"}},{"id":1140426,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71428,"kind":"person","name":"Kelly Paul Edward","position":1,"cik":"0001658544","reported_name":"Kelly Paul Edward","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-05-20T18:03:44.000Z","date":"2025-05-16","kind":"purchase","planned":false,"acquired":true,"shares":200000,"price":0.4303,"value":86060.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $0.4071 to $0.4498 per share, inclusive."}],"balance_after":412295,"source":{"system":"sec-edgar","filing":"0001213900-25-046088","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658544/000121390025046088/ownership.xml","form_type":"4"}},{"id":1140430,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-05-20T18:03:12.000Z","date":"2025-05-20","kind":"purchase","planned":false,"acquired":true,"shares":60000,"price":0.5237,"value":31422.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Purchase prices range from $0.4998 to $0.5396 per share, inclusive."}],"balance_after":288335,"source":{"system":"sec-edgar","filing":"0001213900-25-046087","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390025046087/ownership.xml","form_type":"4"}},{"id":1140429,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-05-20T18:03:12.000Z","date":"2025-05-19","kind":"purchase","planned":false,"acquired":true,"shares":90000,"price":0.4854,"value":43686.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchase prices range from $0.4493 to $0.4998 per share, inclusive."}],"balance_after":228335,"source":{"system":"sec-edgar","filing":"0001213900-25-046087","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390025046087/ownership.xml","form_type":"4"}},{"id":1140428,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-05-20T18:03:12.000Z","date":"2025-05-16","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":0.442,"value":22100.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $0.4229 to $0.4674 per share, inclusive."}],"balance_after":138335,"source":{"system":"sec-edgar","filing":"0001213900-25-046087","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390025046087/ownership.xml","form_type":"4"}},{"id":1382518,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":26788,"kind":"person","name":"CASAMENTO CHARLES J","position":1,"cik":"0001117167","reported_name":"CASAMENTO CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-23T20:27:07.000Z","date":"2024-10-22","kind":"gift","planned":false,"acquired":false,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001213900-24-089971","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117167/000121390024089971/ownership.xml","form_type":"4"}},{"id":1409480,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-11T21:47:15.000Z","date":"2024-09-11","kind":"purchase","planned":false,"acquired":true,"shares":51407,"price":2.99,"value":153706.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Purchase prices range from $2.84 to $3.05 per share, inclusive."}],"balance_after":384024,"source":{"system":"sec-edgar","filing":"0001213900-24-077795","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024077795/ownership.xml","form_type":"4"}},{"id":1409479,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-11T21:47:15.000Z","date":"2024-09-10","kind":"purchase","planned":false,"acquired":true,"shares":33014,"price":2.75,"value":90788.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchase prices range from $2.73 to $2.80 per share, inclusive."}],"balance_after":332617,"source":{"system":"sec-edgar","filing":"0001213900-24-077795","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024077795/ownership.xml","form_type":"4"}},{"id":1409478,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-11T21:47:15.000Z","date":"2024-09-09","kind":"purchase","planned":false,"acquired":true,"shares":55579,"price":2.71,"value":150619.09,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $2.51 to $2.85 per share, inclusive."}],"balance_after":299603,"source":{"system":"sec-edgar","filing":"0001213900-24-077795","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024077795/ownership.xml","form_type":"4"}},{"id":1410108,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":26788,"kind":"person","name":"CASAMENTO CHARLES J","position":1,"cik":"0001117167","reported_name":"CASAMENTO CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-11T21:47:00.000Z","date":"2024-09-09","kind":"purchase","planned":false,"acquired":true,"shares":13000,"price":2.56,"value":33280.0,"ownership":{"direct":true},"balance_after":13000,"source":{"system":"sec-edgar","filing":"0001213900-24-077794","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117167/000121390024077794/ownership.xml","form_type":"4"}},{"id":1409759,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-11T17:46:42.000Z","date":"2024-09-11","kind":"purchase","planned":false,"acquired":true,"shares":24120,"price":2.95,"value":71154.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Purchase prices range from $2.79 to $3.05 per share, inclusive."}],"balance_after":88335,"source":{"system":"sec-edgar","filing":"0001213900-24-077792","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390024077792/ownership.xml","form_type":"4"}},{"id":1409758,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-11T17:46:42.000Z","date":"2024-09-10","kind":"purchase","planned":false,"acquired":true,"shares":21118,"price":2.73,"value":57652.14,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchase prices range from $2.70 to $2.75 per share, inclusive."}],"balance_after":64215,"source":{"system":"sec-edgar","filing":"0001213900-24-077792","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390024077792/ownership.xml","form_type":"4"}},{"id":1409757,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-11T17:46:42.000Z","date":"2024-09-09","kind":"purchase","planned":false,"acquired":true,"shares":8194,"price":2.55,"value":20894.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $2.49 to $2.60 per share, inclusive."}],"balance_after":43097,"source":{"system":"sec-edgar","filing":"0001213900-24-077792","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390024077792/ownership.xml","form_type":"4"}},{"id":1409756,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71428,"kind":"person","name":"Kelly Paul Edward","position":1,"cik":"0001658544","reported_name":"Kelly Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-11T17:46:26.000Z","date":"2024-09-09","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":2.59,"value":64750.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $2.50 to $2.64 per share, inclusive."}],"balance_after":212295,"source":{"system":"sec-edgar","filing":"0001213900-24-077791","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658544/000121390024077791/ownership.xml","form_type":"4"}},{"id":1498839,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T01:25:08.000Z","date":"2024-05-24","kind":"other","planned":false,"acquired":false,"shares":122358,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On May 24, 2024, the Reporting Person voluntarily forfeited to the Issuer a portion of the December Award equal to the Additional Award Shares so that those shares can be allocated to the holders of Similar Awards who are not executive officers or directors of the Issuer."}],"balance_after":183881,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":122358},"source":{"system":"sec-edgar","filing":"0001213900-24-047639","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024047639/ownership.xml","form_type":"4"}},{"id":1498838,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T01:25:08.000Z","date":"2024-05-24","kind":"grant","planned":false,"acquired":true,"shares":122358,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 24, 2024, under the terms of the option award granted to the Reporting Person on December 15, 2023 (the \"December Award\"), the Reporting Person became entitled to receive options for up to 122,358 additional shares of the Issuer's Common Stock on the same terms as the December Award (the \"Additional Award Shares\") out of shares that had become available under the terms of the Issuer's 2021 Equity Incentive Plan, as amended (the \"Plan\"), since December 15, 2023, as a result of expirations, cancelations, forfeitures and terminations of other outstanding awards under the Plan and/or tenders or withholding of shares."}],"balance_after":306239,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":122358},"source":{"system":"sec-edgar","filing":"0001213900-24-047639","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024047639/ownership.xml","form_type":"4"}},{"id":1498837,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71407,"kind":"person","name":"GLASSPOOL JOHN","position":1,"cik":"0001644079","reported_name":"GLASSPOOL JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T01:24:26.000Z","date":"2024-05-24","kind":"other","planned":false,"acquired":false,"shares":20976,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On May 24, 2024, the Reporting Person voluntarily forfeited to the Issuer a portion of the December Award equal to the Additional Award Shares so that those shares can be allocated to the holders of Similar Awards who are not executive officers or directors of the Issuer."}],"balance_after":31522,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":20976},"source":{"system":"sec-edgar","filing":"0001213900-24-047636","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024047636/ownership.xml","form_type":"4"}},{"id":1498836,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71407,"kind":"person","name":"GLASSPOOL JOHN","position":1,"cik":"0001644079","reported_name":"GLASSPOOL JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T01:24:26.000Z","date":"2024-05-24","kind":"grant","planned":false,"acquired":true,"shares":20976,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 24, 2024, under the terms of the option award granted to the Reporting Person on December 15, 2023 (the \"December Award\"), the Reporting Person became entitled to receive options for up to 20,976 additional shares of the Issuer's Common Stock on the same terms as the December Award (the \"Additional Award Shares\") out of shares that had become available under the terms of the Issuer's 2021 Equity Incentive Plan, as amended (the \"Plan\"), since December 15, 2023, as a result of expirations, cancelations, forfeitures and terminations of other outstanding awards under the Plan and/or tenders or withholding of shares."}],"balance_after":52498,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":20976},"source":{"system":"sec-edgar","filing":"0001213900-24-047636","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024047636/ownership.xml","form_type":"4"}},{"id":1498835,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71408,"kind":"person","name":"Fedeli Fabiana","position":1,"cik":"0001961902","reported_name":"Fedeli Fabiana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T01:24:12.000Z","date":"2024-05-24","kind":"other","planned":false,"acquired":false,"shares":20976,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On May 24, 2024, the Reporting Person voluntarily forfeited to the Issuer a portion of the December Award equal to the Additional Award Shares so that those shares can be allocated to the holders of Similar Awards who are not executive officers or directors of the Issuer."}],"balance_after":31522,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":20976},"source":{"system":"sec-edgar","filing":"0001213900-24-047635","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024047635/ownership.xml","form_type":"4"}},{"id":1498834,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71408,"kind":"person","name":"Fedeli Fabiana","position":1,"cik":"0001961902","reported_name":"Fedeli Fabiana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T01:24:12.000Z","date":"2024-05-24","kind":"grant","planned":false,"acquired":true,"shares":20976,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 24, 2024, under the terms of the option award granted to the Reporting Person on December 15, 2023 (the \"December Award\"), the Reporting Person became entitled to receive options for up to 20,976 additional shares of the Issuer's Common Stock on the same terms as the December Award (the \"Additional Award Shares\") out of shares that had become available under the terms of the Issuer's 2021 Equity Incentive Plan, as amended (the \"Plan\"), since December 15, 2023, as a result of expirations, cancelations, forfeitures and terminations of other outstanding awards under the Plan and/or tenders or withholding of shares."}],"balance_after":52498,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":20976},"source":{"system":"sec-edgar","filing":"0001213900-24-047635","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024047635/ownership.xml","form_type":"4"}},{"id":1498833,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71409,"kind":"person","name":"Ence Chuck","position":1,"cik":"0001697779","reported_name":"Ence Chuck","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CA and CO"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T01:23:59.000Z","date":"2024-05-24","kind":"other","planned":false,"acquired":false,"shares":54624,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On May 24, 2024, the Reporting Person voluntarily forfeited to the Issuer a portion of the December Award equal to the Additional Award Shares so that those shares can be allocated to the holders of Similar Awards who are not executive officers or directors of the Issuer."}],"balance_after":82090,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":54624},"source":{"system":"sec-edgar","filing":"0001213900-24-047633","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024047633/ownership.xml","form_type":"4"}},{"id":1498832,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71409,"kind":"person","name":"Ence Chuck","position":1,"cik":"0001697779","reported_name":"Ence Chuck","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CA and CO"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T01:23:59.000Z","date":"2024-05-24","kind":"grant","planned":false,"acquired":true,"shares":54624,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 24, 2024, under the terms of the option award granted to the Reporting Person on December 15, 2023 (the \"December Award\"), the Reporting Person became entitled to receive options for up to 54,624 additional shares of the Issuer's Common Stock on the same terms as the December Award (the \"Additional Award Shares\") out of shares that had become available under the terms of the Issuer's 2021 Equity Incentive Plan, as amended (the \"Plan\"), since December 15, 2023, as a result of expirations, cancelations, forfeitures and terminations of other outstanding awards under the Plan and/or tenders or withholding of shares."}],"balance_after":136714,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":54624},"source":{"system":"sec-edgar","filing":"0001213900-24-047633","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024047633/ownership.xml","form_type":"4"}},{"id":1499420,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":26788,"kind":"person","name":"CASAMENTO CHARLES J","position":1,"cik":"0001117167","reported_name":"CASAMENTO CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T01:23:44.000Z","date":"2024-05-24","kind":"other","planned":false,"acquired":false,"shares":20976,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On May 24, 2024, the Reporting Person voluntarily forfeited to the Issuer a portion of the December Award equal to the Additional Award Shares so that those shares can be allocated to the holders of Similar Awards who are not executive officers or directors of the Issuer."}],"balance_after":31522,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":20976},"source":{"system":"sec-edgar","filing":"0001213900-24-047632","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1117167/000121390024047632/ownership.xml","form_type":"4"}},{"id":1499419,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":26788,"kind":"person","name":"CASAMENTO CHARLES J","position":1,"cik":"0001117167","reported_name":"CASAMENTO CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T01:23:44.000Z","date":"2024-05-24","kind":"grant","planned":false,"acquired":true,"shares":20976,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 24, 2024, under the terms of the option award granted to the Reporting Person on December 15, 2023 (the \"December Award\"), the Reporting Person became entitled to receive options for up to 20,976 additional shares of the Issuer's Common Stock on the same terms as the December Award (the \"Additional Award Shares\") out of shares that had become available under the terms of the Issuer's 2021 Equity Incentive Plan, as amended (the \"Plan\"), since December 15, 2023, as a result of expirations, cancelations, forfeitures and terminations of other outstanding awards under the Plan and/or tenders or withholding of shares."}],"balance_after":52498,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":20976},"source":{"system":"sec-edgar","filing":"0001213900-24-047632","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117167/000121390024047632/ownership.xml","form_type":"4"}},{"id":1499141,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-29T21:24:53.000Z","date":"2024-05-24","kind":"other","planned":false,"acquired":false,"shares":54624,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On May 24, 2024, the Reporting Person voluntarily forfeited to the Issuer a portion of the December Award equal to the Additional Award Shares so that those shares can be allocated to the holders of Similar Awards who are not executive officers or directors of the Issuer."}],"balance_after":82090,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":54624},"source":{"system":"sec-edgar","filing":"0001213900-24-047638","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390024047638/ownership.xml","form_type":"4"}},{"id":1499140,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-29T21:24:53.000Z","date":"2024-05-24","kind":"grant","planned":false,"acquired":true,"shares":54624,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 24, 2024, under the terms of the option award granted to the Reporting Person on December 15, 2023 (the \"December Award\"), the Reporting Person became entitled to receive options for up to 54,624 additional shares of the Issuer's Common Stock on the same terms as the December Award (the \"Additional Award Shares\") out of shares that had become available under the terms of the Issuer's 2021 Equity Incentive Plan, as amended (the \"Plan\"), since December 15, 2023, as a result of expirations, cancelations, forfeitures and terminations of other outstanding awards under the Plan and/or tenders or withholding of shares."}],"balance_after":136714,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":54624},"source":{"system":"sec-edgar","filing":"0001213900-24-047638","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390024047638/ownership.xml","form_type":"4"}},{"id":1499135,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71428,"kind":"person","name":"Kelly Paul Edward","position":1,"cik":"0001658544","reported_name":"Kelly Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-29T21:24:40.000Z","date":"2024-05-24","kind":"other","planned":false,"acquired":false,"shares":43700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On May 24, 2024, the Reporting Person voluntarily forfeited to the Issuer a portion of the December Award equal to the Additional Award Shares so that those shares can be allocated to the holders of Similar Awards who are not executive officers or directors of the Issuer."}],"balance_after":65672,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":43700},"source":{"system":"sec-edgar","filing":"0001213900-24-047637","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658544/000121390024047637/ownership.xml","form_type":"4"}},{"id":1499134,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71428,"kind":"person","name":"Kelly Paul Edward","position":1,"cik":"0001658544","reported_name":"Kelly Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-29T21:24:40.000Z","date":"2024-05-24","kind":"grant","planned":false,"acquired":true,"shares":43700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 24, 2024, under the terms of the option award granted to the Reporting Person on December 15, 2023 (the \"December Award\"), the Reporting Person became entitled to receive options for up to 43,700 additional shares of the Issuer's Common Stock on the same terms as the December Award (the \"Additional Award Shares\") out of shares that had become available under the terms of the Issuer's 2021 Equity Incentive Plan, as amended (the \"Plan\"), since December 15, 2023, as a result of expirations, cancelations, forfeitures and terminations of other outstanding awards under the Plan and/or tenders or withholding of shares."}],"balance_after":109372,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":43700},"source":{"system":"sec-edgar","filing":"0001213900-24-047637","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658544/000121390024047637/ownership.xml","form_type":"4"}},{"id":1664883,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-31T23:29:27.000Z","date":"2024-01-31","kind":"purchase","planned":false,"acquired":true,"shares":27460,"price":3.9968,"value":109752.128,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Purchase prices range from $3.95 to $4.05 per share, inclusive."}],"balance_after":244024,"source":{"system":"sec-edgar","filing":"0001213900-24-008560","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024008560/ownership.xml","form_type":"4"}},{"id":1664882,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-31T23:29:27.000Z","date":"2024-01-30","kind":"purchase","planned":false,"acquired":true,"shares":40999,"price":3.9013,"value":159949.3987,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchase prices range from $3.88 to $3.97 per share, inclusive."}],"balance_after":216564,"source":{"system":"sec-edgar","filing":"0001213900-24-008560","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024008560/ownership.xml","form_type":"4"}},{"id":1664881,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-31T23:29:27.000Z","date":"2024-01-29","kind":"purchase","planned":false,"acquired":true,"shares":31541,"price":3.7106,"value":117036.0346,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $3.69 to $3.75 per share, inclusive."}],"balance_after":175565,"source":{"system":"sec-edgar","filing":"0001213900-24-008560","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024008560/ownership.xml","form_type":"4"}},{"id":1664880,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71409,"kind":"person","name":"Ence Chuck","position":1,"cik":"0001697779","reported_name":"Ence Chuck","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CA and CO"}}],"security":"Common Stock","published_at":"2024-01-31T23:28:02.000Z","date":"2024-01-31","kind":"purchase","planned":false,"acquired":true,"shares":13670,"price":4.0548,"value":55429.116,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Purchase prices range from $3.93 to $4.17 per share, inclusive."}],"balance_after":38970,"source":{"system":"sec-edgar","filing":"0001213900-24-008557","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024008557/ownership.xml","form_type":"4"}},{"id":1664879,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71409,"kind":"person","name":"Ence Chuck","position":1,"cik":"0001697779","reported_name":"Ence Chuck","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CA and CO"}}],"security":"Common Stock","published_at":"2024-01-31T23:28:02.000Z","date":"2024-01-30","kind":"purchase","planned":false,"acquired":true,"shares":14500,"price":3.8657,"value":56052.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchase prices range from $3.755 to $3.99 per share, inclusive."}],"balance_after":25300,"source":{"system":"sec-edgar","filing":"0001213900-24-008557","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024008557/ownership.xml","form_type":"4"}},{"id":1664878,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71409,"kind":"person","name":"Ence Chuck","position":1,"cik":"0001697779","reported_name":"Ence Chuck","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CA and CO"}}],"security":"Common Stock","published_at":"2024-01-31T23:28:02.000Z","date":"2024-01-29","kind":"purchase","planned":false,"acquired":true,"shares":10800,"price":3.6517,"value":39438.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $3.585 to $3.73 per share, inclusive."}],"balance_after":10800,"source":{"system":"sec-edgar","filing":"0001213900-24-008557","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024008557/ownership.xml","form_type":"4"}},{"id":1665178,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-31T18:28:58.000Z","date":"2024-01-31","kind":"purchase","planned":false,"acquired":true,"shares":6875,"price":4.0645,"value":27943.4375,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Purchase prices range from $3.95 to $4.18 per share, inclusive."}],"balance_after":34903,"source":{"system":"sec-edgar","filing":"0001213900-24-008559","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390024008559/ownership.xml","form_type":"4"}},{"id":1665177,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-31T18:28:58.000Z","date":"2024-01-30","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":3.8882,"value":58323.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchase prices range from $3.82 to $3.90 per share, inclusive."}],"balance_after":28028,"source":{"system":"sec-edgar","filing":"0001213900-24-008559","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390024008559/ownership.xml","form_type":"4"}},{"id":1665176,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-31T18:28:58.000Z","date":"2024-01-29","kind":"purchase","planned":false,"acquired":true,"shares":10800,"price":3.6528,"value":39450.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $3.57 to $3.745 per share, inclusive."}],"balance_after":13028,"source":{"system":"sec-edgar","filing":"0001213900-24-008559","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390024008559/ownership.xml","form_type":"4"}},{"id":1704384,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-12-19T22:28:56.000Z","date":"2023-12-15","kind":"grant","planned":false,"acquired":true,"shares":183881,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 16 equal quarterly installments commencing on March 15, 2024."}],"balance_after":183881,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":183881},"source":{"system":"sec-edgar","filing":"0001213900-23-097032","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023097032/ownership.xml","form_type":"4"}},{"id":1704383,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71407,"kind":"person","name":"GLASSPOOL JOHN","position":1,"cik":"0001644079","reported_name":"GLASSPOOL JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-12-19T22:27:59.000Z","date":"2023-12-15","kind":"grant","planned":false,"acquired":true,"shares":31522,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 16 equal quarterly installments commencing on March 15, 2024."}],"balance_after":31522,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":31522},"source":{"system":"sec-edgar","filing":"0001213900-23-097028","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023097028/ownership.xml","form_type":"4"}},{"id":1704382,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71408,"kind":"person","name":"Fedeli Fabiana","position":1,"cik":"0001961902","reported_name":"Fedeli Fabiana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-12-19T22:27:35.000Z","date":"2023-12-15","kind":"grant","planned":false,"acquired":true,"shares":31522,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 16 equal quarterly installments commencing on March 15, 2024."}],"balance_after":31522,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":31522},"source":{"system":"sec-edgar","filing":"0001213900-23-097027","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023097027/ownership.xml","form_type":"4"}},{"id":1704380,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71409,"kind":"person","name":"Ence Chuck","position":1,"cik":"0001697779","reported_name":"Ence Chuck","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting and CO"}}],"security":"Stock Option (right to buy)","published_at":"2023-12-19T22:27:18.000Z","date":"2023-12-15","kind":"grant","planned":false,"acquired":true,"shares":82090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 16 equal quarterly installments commencing on March 15, 2024."}],"balance_after":82090,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":82090},"source":{"system":"sec-edgar","filing":"0001213900-23-097026","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023097026/ownership.xml","form_type":"4"}},{"id":1705384,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":26788,"kind":"person","name":"CASAMENTO CHARLES J","position":1,"cik":"0001117167","reported_name":"CASAMENTO CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-12-19T22:26:46.000Z","date":"2023-12-15","kind":"grant","planned":false,"acquired":true,"shares":31522,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 16 equal quarterly installments commencing on March 15, 2024."}],"balance_after":31522,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":31522},"source":{"system":"sec-edgar","filing":"0001213900-23-097024","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117167/000121390023097024/ownership.xml","form_type":"4"}},{"id":1704874,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-12-19T17:28:31.000Z","date":"2023-12-15","kind":"grant","planned":false,"acquired":true,"shares":82090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 16 equal quarterly installments commencing on March 15, 2024."}],"balance_after":82090,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":82090},"source":{"system":"sec-edgar","filing":"0001213900-23-097031","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390023097031/ownership.xml","form_type":"4"}},{"id":1704870,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71428,"kind":"person","name":"Kelly Paul Edward","position":1,"cik":"0001658544","reported_name":"Kelly Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-12-19T17:28:09.000Z","date":"2023-12-15","kind":"grant","planned":false,"acquired":true,"shares":65672,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 16 equal quarterly installments commencing on March 15, 2024."}],"balance_after":65672,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":65672},"source":{"system":"sec-edgar","filing":"0001213900-23-097029","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658544/000121390023097029/ownership.xml","form_type":"4"}},{"id":1874291,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-05-30T21:10:46.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":527211,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the Board of Directors of the Company on December 16, 2022, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the \"Plan\"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"80,728 of the options immediately vested; 770,000 options vest in 16 equal quarterly installments commencing on March 16, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"80,728 of the options immediately vested; 770,000 options vest in 16 equal quarterly installments commencing on March 16, 2023."}],"balance_after":850728,"derivative":{"exercise_price":3.37,"exercise_date":"2022-12-16","expiration_date":"2032-12-16","underlying":"Common Stock","underlying_shares":527211},"source":{"system":"sec-edgar","filing":"0001213900-23-044093","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023044093/ownership.xml","form_type":"4"}},{"id":1874290,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":112425,"kind":"person","name":"SCHMIDT ERIC THOMAS","position":1,"cik":"0001754403","reported_name":"SCHMIDT ERIC THOMAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-30T21:09:03.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":92958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the Board of Directors of the Company on December 16, 2022, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the \"Plan\"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in 16 equal quarterly installments commencing on March 16, 2023."}],"balance_after":150000,"derivative":{"exercise_price":3.37,"exercise_date":"2023-03-16","expiration_date":"2032-12-16","underlying":"Common Stock","underlying_shares":92958},"source":{"system":"sec-edgar","filing":"0001213900-23-044088","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023044088/ownership.xml","form_type":"4"}},{"id":1874289,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71407,"kind":"person","name":"GLASSPOOL JOHN","position":1,"cik":"0001644079","reported_name":"GLASSPOOL JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-30T21:08:06.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":92958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the Board of Directors of the Company on December 16, 2022, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the \"Plan\"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in 16 equal quarterly installments commencing on March 16, 2023."}],"balance_after":150000,"derivative":{"exercise_price":3.37,"exercise_date":"2023-03-16","expiration_date":"2032-12-16","underlying":"Common Stock","underlying_shares":92958},"source":{"system":"sec-edgar","filing":"0001213900-23-044084","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023044084/ownership.xml","form_type":"4"}},{"id":1874288,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71408,"kind":"person","name":"Fedeli Fabiana","position":1,"cik":"0001961902","reported_name":"Fedeli Fabiana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-30T21:06:45.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the Board of Directors of the Company on January 12, 2023, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the \"Plan\"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the option vests on the first anniversary of the date grant and the remaining 75% in equal increments of 6.25% of the total options at the end of each three-month interval over the following three year period."}],"balance_after":200000,"derivative":{"exercise_price":4.22,"exercise_date":"2024-01-12","expiration_date":"2033-01-12","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001213900-23-044083","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023044083/ownership.xml","form_type":"4"}},{"id":1874287,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71409,"kind":"person","name":"Ence Chuck","position":1,"cik":"0001697779","reported_name":"Ence Chuck","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CA and CO"}}],"security":"Stock Option (right to buy)","published_at":"2023-05-30T21:06:12.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":321238,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the Board of Directors of the Company on December 16, 2022, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the \"Plan\"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"18,361 of the options immediately vested; 500,000 options vest in 16 equal quarterly installments commencing on March 16, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"18,361 of the options immediately vested; 500,000 options vest in 16 equal quarterly installments commencing on March 16, 2023."}],"balance_after":518361,"derivative":{"exercise_price":3.37,"exercise_date":"2022-12-16","expiration_date":"2032-12-16","underlying":"Common Stock","underlying_shares":321238},"source":{"system":"sec-edgar","filing":"0001213900-23-044081","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023044081/ownership.xml","form_type":"4"}},{"id":1875233,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":26788,"kind":"person","name":"CASAMENTO CHARLES J","position":1,"cik":"0001117167","reported_name":"CASAMENTO CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-30T21:05:44.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":92958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the Board of Directors of the Company on December 16, 2022, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the \"Plan\"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in 16 equal quarterly installments commencing on March 16, 2023."}],"balance_after":150000,"derivative":{"exercise_price":3.37,"exercise_date":"2023-03-16","expiration_date":"2032-12-16","underlying":"Common Stock","underlying_shares":92958},"source":{"system":"sec-edgar","filing":"0001213900-23-044079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117167/000121390023044079/ownership.xml","form_type":"4"}},{"id":1874846,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71429,"kind":"person","name":"Shenouda Maged","position":1,"cik":"0001658369","reported_name":"Shenouda Maged","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-05-30T17:09:53.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":317643,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the Board of Directors of the Company on December 16, 2022, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the \"Plan\"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"62,560 of the options immediately vested; 450,000 options vest in 16 equal quarterly installments commencing on March 16, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"62,560 of the options immediately vested; 450,000 options vest in 16 equal quarterly installments commencing on March 16, 2023."}],"balance_after":512560,"derivative":{"exercise_price":3.37,"exercise_date":"2023-03-16","expiration_date":"2032-12-16","underlying":"Common Stock","underlying_shares":317643},"source":{"system":"sec-edgar","filing":"0001213900-23-044089","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658369/000121390023044089/ownership.xml","form_type":"4"}},{"id":1874845,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71428,"kind":"person","name":"Kelly Paul Edward","position":1,"cik":"0001658544","reported_name":"Kelly Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-30T17:08:31.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":92958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the Board of Directors of the Company on December 16, 2022, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the \"Plan\"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in 16 equal quarterly installments commencing on March 16, 2023."}],"balance_after":150000,"derivative":{"exercise_price":3.37,"exercise_date":"2023-03-16","expiration_date":"2032-12-16","underlying":"Common Stock","underlying_shares":92958},"source":{"system":"sec-edgar","filing":"0001213900-23-044087","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658544/000121390023044087/ownership.xml","form_type":"4"}},{"id":1879406,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":113159,"kind":"person","name":"O'Gorman Cedric","position":1,"cik":"0001962179","reported_name":"O'Gorman Cedric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-05-24T13:00:22.000Z","date":"2023-05-23","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":3.18,"value":31800.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $3.135 to $3.2096 per share, inclusive."}],"balance_after":10121,"source":{"system":"sec-edgar","filing":"0001213900-23-042554","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023042554/ownership.xml","form_type":"4"}},{"id":2030241,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-06T22:39:14.000Z","date":"2022-09-28","kind":"gift","acquired":false,"shares":87500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The options were granted on January 7, 2021. 25% of the options vested one year from the grant date, and thereafter in equal quarterly increments of 6.25% over the following three years."}],"balance_after":162500,"derivative":{"exercise_price":33.43,"expiration_date":"2031-01-07","underlying":"Common Stock","underlying_shares":87500},"source":{"system":"sec-edgar","filing":"0001213900-23-008514","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023008514/ownership.xml","form_type":"5/A","original_submission_date":"2023-02-02"}},{"id":2030240,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-06T22:39:14.000Z","date":"2022-09-28","kind":"gift","acquired":false,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options were granted on January 7, 2021. 6.25% of the options vest each quarter from the date of grant."}],"balance_after":162500,"derivative":{"exercise_price":33.43,"expiration_date":"2031-01-07","underlying":"Common Stock","underlying_shares":62500},"source":{"system":"sec-edgar","filing":"0001213900-23-008514","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023008514/ownership.xml","form_type":"5/A","original_submission_date":"2023-02-02"}},{"id":2030239,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-06T22:39:14.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options were granted on January 7, 2021. 6.25% of the options vest each quarter from the date of grant."}],"balance_after":225000,"derivative":{"exercise_price":33.43,"expiration_date":"2031-01-07","underlying":"Common Stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0001213900-23-008514","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023008514/ownership.xml","form_type":"5/A","original_submission_date":"2023-02-02"}},{"id":2030238,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-06T22:39:14.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":131250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options were granted on December 19, 2019. 6.25% of the options vest each quarter from the date of grant."}],"balance_after":218750,"derivative":{"exercise_price":43.47,"expiration_date":"2029-12-19","underlying":"Common Stock","underlying_shares":131250},"source":{"system":"sec-edgar","filing":"0001213900-23-008514","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023008514/ownership.xml","form_type":"5/A","original_submission_date":"2023-02-02"}},{"id":2030237,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-06T22:39:14.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":8231,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options were granted on February 15, 2015. 6.25% of the options vested each quarter from the date of grant."}],"balance_after":3019,"derivative":{"exercise_price":54,"expiration_date":"2025-02-23","underlying":"Common Stock","underlying_shares":8231},"source":{"system":"sec-edgar","filing":"0001213900-23-008514","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023008514/ownership.xml","form_type":"5/A","original_submission_date":"2023-02-02"}},{"id":2030236,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-06T22:39:14.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":27123,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options were granted on September 30, 2013. 25% of the options vested upon the date of grant and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in September 2017."}],"balance_after":6165,"derivative":{"exercise_price":16,"expiration_date":"2023-09-30","underlying":"Common Stock","underlying_shares":27123},"source":{"system":"sec-edgar","filing":"0001213900-23-008514","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023008514/ownership.xml","form_type":"5/A","original_submission_date":"2023-02-02"}},{"id":2030235,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-06T22:39:14.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":4131,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted on July 10, 2012. 25% of the options vested upon the grant date and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in July 2016."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2022-07-10","underlying":"Common Stock","underlying_shares":4131},"source":{"system":"sec-edgar","filing":"0001213900-23-008514","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023008514/ownership.xml","form_type":"5/A","original_submission_date":"2023-02-02"}},{"id":2035232,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T22:01:35.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":87500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The options were granted on January 7, 2021. 25% of the options vested one year from the grant date, and thereafter in equal quarterly increments of 6.25% over the following three years."}],"balance_after":162500,"derivative":{"exercise_price":33.43,"expiration_date":"2031-01-07","underlying":"Common Stock","underlying_shares":87500},"source":{"system":"sec-edgar","filing":"0001213900-23-007440","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023007440/ownership.xml","form_type":"5"}},{"id":2035231,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T22:01:35.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":93750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options were granted on January 7, 2021. 6.25% of the options vest each quarter from the date of grant."}],"balance_after":162500,"derivative":{"exercise_price":33.43,"expiration_date":"2031-01-07","underlying":"Common Stock","underlying_shares":93750},"source":{"system":"sec-edgar","filing":"0001213900-23-007440","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023007440/ownership.xml","form_type":"5"}},{"id":2035230,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T22:01:35.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":131250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options were granted on December 19, 2019. 6.25% of the options vest each quarter from the date of grant."}],"balance_after":218750,"derivative":{"exercise_price":43.47,"expiration_date":"2029-12-19","underlying":"Common Stock","underlying_shares":131250},"source":{"system":"sec-edgar","filing":"0001213900-23-007440","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023007440/ownership.xml","form_type":"5"}},{"id":2035229,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T22:01:35.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":8231,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options were granted on February 15, 2015. 6.25% of the options vested each quarter from the date of grant."}],"balance_after":3019,"derivative":{"exercise_price":54,"expiration_date":"2025-02-23","underlying":"Common Stock","underlying_shares":8231},"source":{"system":"sec-edgar","filing":"0001213900-23-007440","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023007440/ownership.xml","form_type":"5"}},{"id":2035228,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T22:01:35.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":27123,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options were granted on September 30, 2013. 25% of the options vested upon the date of grant and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in September 2017."}],"balance_after":6165,"derivative":{"exercise_price":16,"expiration_date":"2023-09-30","underlying":"Common Stock","underlying_shares":27123},"source":{"system":"sec-edgar","filing":"0001213900-23-007440","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023007440/ownership.xml","form_type":"5"}},{"id":2035227,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T22:01:35.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":4131,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted on July 10, 2012. 25% of the options vested upon the grant date and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in July 2016."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2022-07-10","underlying":"Common Stock","underlying_shares":4131},"source":{"system":"sec-edgar","filing":"0001213900-23-007440","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023007440/ownership.xml","form_type":"5"}},{"id":2036699,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":26788,"kind":"person","name":"CASAMENTO CHARLES J","position":1,"cik":"0001117167","reported_name":"CASAMENTO CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-02T22:00:31.000Z","date":"2021-12-03","kind":"gift","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By The La Jolla Lenox Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 3, 2021, the Reporting Person transferred 10,000 shares of the Issuer's common stock to a family trust of which the Trustee is someone other than the Reporting Person. The Reporting Person and members of his immediate family are the sole beneficiaries of the trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the filing of this report is not an admission that The Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001213900-23-007436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1117167/000121390023007436/ownership.xml","form_type":"5"}},{"id":2036698,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":26788,"kind":"person","name":"CASAMENTO CHARLES J","position":1,"cik":"0001117167","reported_name":"CASAMENTO CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-02T22:00:31.000Z","date":"2021-12-03","kind":"gift","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001213900-23-007436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117167/000121390023007436/ownership.xml","form_type":"5"}},{"id":2036099,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71428,"kind":"person","name":"Kelly Paul Edward","position":1,"cik":"0001658544","reported_name":"Kelly Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T17:00:59.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to family members and a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options were granted on January 7, 2021. 6.25% of the options vest each quarter from the date of grant."}],"balance_after":132000,"derivative":{"exercise_price":33.43,"expiration_date":"2031-01-07","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001213900-23-007438","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658544/000121390023007438/ownership.xml","form_type":"5"}},{"id":2036098,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71428,"kind":"person","name":"Kelly Paul Edward","position":1,"cik":"0001658544","reported_name":"Kelly Paul Edward","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T17:00:59.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to family members and a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options were granted on December 19, 2019. 6.25% of the options vest each quarter from the date of grant."}],"balance_after":94000,"derivative":{"exercise_price":43.47,"expiration_date":"2029-12-19","underlying":"Common Stock","underlying_shares":56000},"source":{"system":"sec-edgar","filing":"0001213900-23-007438","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658544/000121390023007438/ownership.xml","form_type":"5"}}],"next_cursor":"2023-02-02T17:00:59.000000Z,2036098"}